{"document_type": "article", "byline": {"person": [{"role": "reported", "firstname": "Katie", "organization": "", "rank": 1, "lastname": "THOMAS"}], "original": "By KATIE THOMAS"}, "news_desk": "Business", "slideshow_credits": null, "abstract": "Valeant Pharmaceuticals chief executive Joseph C Papa tells analysts that he is optimistic about company's future; company reports loss of almost $374 million in first quarter, revealing troubles in its core business areas.", "multimedia": [{"type": "image", "url": "images/2016/06/08/business/08valeant/08valeant-thumbWide.jpg", "legacy": {"wide": "images/2016/06/08/business/08valeant/08valeant-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "width": 190, "subtype": "wide", "height": 126}, {"type": "image", "url": "images/2016/06/08/business/08valeant/08valeant-articleLarge.jpg", "legacy": {"xlarge": "images/2016/06/08/business/08valeant/08valeant-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "400"}, "width": 600, "subtype": "xlarge", "height": 400}, {"type": "image", "url": "images/2016/06/08/business/08valeant/08valeant-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/06/08/business/08valeant/08valeant-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "width": 75, "subtype": "thumbnail", "height": 75}], "headline": {"print_headline": "Valeant Reports First-Quarter Loss as Chief Assures Bright Future", "main": "Valeant Reports First-Quarter Loss and Cuts Its Forecast"}, "print_page": "2", "keywords": [{"value": "Valeant Pharmaceuticals International Inc", "is_major": "Y", "rank": "1", "name": "organizations"}, {"value": "Papa, Joseph C", "is_major": "Y", "rank": "2", "name": "persons"}, {"value": "Company Reports", "is_major": "N", "rank": "3", "name": "subject"}, {"value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "4", "name": "subject"}], "snippet": "Valeant, the pharmaceuticals company facing questions about its business and accounting practices, said it lost nearly $374 million in the quarter.", "source": "The New York Times", "lead_paragraph": "Valeant, the pharmaceuticals company facing questions about its business and accounting practices, said it lost nearly $374 million in the quarter.", "word_count": "797", "pub_date": "2016-06-08T00:00:00Z", "subsection_name": null, "blog": [], "type_of_material": "News", "section_name": "Business Day", "web_url": "http://www.nytimes.com/2016/06/08/business/valeant-q1-earnings.html", "_id": "5756d0a038f0d839b19249f9"}